Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement75.75 M1.25 B243.26 M239.57 M363.44 M377.18 M405.91 MFlux de trésorerie liés aux activités de financement261.52 M-765.77 M2.35 M5.43 M14.44 M8.68 M9.13 MFlux de trésorerie disponible-290.76 M-407.32 M-309.48 M-296.06 M-389.84 M-377.29 M-384.73 M
Agios Pharmaceuticals, Inc. - Common Stock
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.